InMed Pharmaceuticals Inc. (INM)

NASDAQ: INM · IEX Real-Time Price · USD

0.303

+0.030 (10.99%)

At close: Apr 24, 2024, 4:00 PM

0.281

-0.022 (-7.26%)

Pre-market: Apr 25, 2024, 4:42 AM EDT

InMed Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is July - June.

Millions USD. Fiscal year is Jul - Jun.

Year	2023	2022	2021	2020	2019
Revenue	4.14	1.09	0	0	0
Revenue Growth (YoY)	279.61%	-	-	-	-
Cost of Revenue	2.73	0.55	0	0	0
Gross Profit	1.4	0.54	0	0	0
Selling, General & Admin	5.85	6.87	4.48	3.23	4.3
Research & Development	3.73	7.28	5.34	5.81	5.13
Other Operating Expenses	0.2	3.66	0.12	0.11	0.12
Operating Expenses	9.78	17.81	9.94	9.15	9.54
Operating Income	-8.38	-17.26	-9.94	-9.15	-9.54
Interest Expense / Income	0	0	0.36	0	0
Other Expense / Income	-0.44	1.34	-0.1	-0.21	-0.29
Pretax Income	-7.93	-18.6	-10.2	-8.94	-9.25
Income Tax	0.01	0	0	0	0
Net Income	-7.95	-18.6	-10.2	-8.94	-9.25
Shares Outstanding (Basic)	2	1	0	0	0
Shares Outstanding (Diluted)	2	1	0	0	0
Shares Change	336.58%	108.65%	28.72%	0.55%	-
EPS (Basic)	-3.25	-33.17	-37.96	-42.75	-44.50
EPS (Diluted)	-3.25	-33.17	-37.96	-42.75	-44.50
Free Cash Flow	-7.45	-15.62	-9.79	-7.42	-6.65
Free Cash Flow Per Share	-3.04	-27.86	-36.43	-35.52	-32.02
Gross Margin	33.93%	49.89%	-	-	-
Operating Margin	-202.60%	-1584.71%	-	-	-
Profit Margin	-192.18%	-1707.32%	-	-	-
Free Cash Flow Margin	-180.02%	-1434.03%	-	-	-
EBITDA	-7.34	-18.09	-9.61	-8.74	-9.13
EBITDA Margin	-177.45%	-1660.34%	-	-	-
Depreciation & Amortization	0.6	0.51	0.23	0.2	0.12
EBIT	-7.93	-18.6	-9.84	-8.94	-9.25
EBIT Margin	-191.86%	-1707.32%	-	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).